Early identification of cirrhosis risk in type 2 diabetes using the Fibrosis-4 index: evidence from a large U.S. cohort.
A simple liver fibrosis score catches undetected cirrhosis risk in diabetic patients during routine care, enabling earlier intervention.
Using a large U.S. diabetes cohort, this study validated FIB-4 as an accessible laboratory-based tool for early liver fibrosis detection in T2D, identifying a substantial population at undetected cirrhosis risk. FIB-4 screening integrated into routine diabetes care could enable early intervention before end-stage liver disease develops.
What the study was
- Study design
- Large retrospective U.S. cohort study
- Category
- Other
- Maturity
- Validated
- Journal
- BMC Endocr Disord
Why it surfaced
Large U.S. cohort validating FIB-4 for non-invasive liver fibrosis screening in T2D; actionable data for cardiometabolic risk stratification; relevant to T7 watchlist.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.